Theodore R. Schroeder - 29 Jan 2022 Form 4 Insider Report for Nabriva Therapeutics plc

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
N/A
Transactions as of
29 Jan 2022
Net transactions value
-$4,905
Form type
4
Filing time
01 Feb 2022, 19:47:10 UTC
Previous filing
01 Feb 2022
Next filing
08 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRV Ordinary Shares Tax liability $4,845 -10,766 -3.3% $0.4500 314,736 29 Jan 2022 Direct F1
transaction NBRV Ordinary Shares Tax liability $60 -125 -0.04% $0.4800 314,611 31 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.